The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.

Inclusion Criteria:

• Clinical diagnosis of ocular hypertension, primary open-angle glaucoma or pigmentary glaucoma;
• Intraocular pressure (IOP) of between 19 to 35 mmHg at any time of the day in at least one eye (designated as the study eye);
• On a stable medication regimen for IOP reduction one week prior to the screening visit;
• Best corrected visual acuity better than 20/200 (Snellen) or 1.0 (logMAR) in each eye;
• Sign informed consent;
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Known medical history of allergy, hypersensitivity or low tolerance to any of the components of DuoTrav®;
• Any abnormality that would preclude the reliable performance of applanation tonometry in either eye;
• Infection in either eye;
• Conventional or laser intraocular surgery in either eye 3 months prior to screening visit;
• Risk for visual field or visual acuity worsening, in the opinion of the investigator;
• Women of childbearing potential;
• Pregnant or lactating women;
• Any condition that, in the opinion of the principal investigator, could interfere with participation in the study, or that could present a risk to the participant.
• Participation in another clinical study within 30 days before the screening visit;
• Other protocol-defined exclusion criteria may apply.

This reporting group includes all participants who received study product.

Adverse events were collected for the duration of the study.

This reporting group includes all participants who received study product.